The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Re-rate = Multi Bagger = ££££
Re rate incoming. I can see at least £5 a share...
Payments up to $700 Million.
Mcap =£90 Million.
Mallinckrodt has agreed to provide Silence with an upfront payment of $20 million. Silence is also eligible to receive up to $10 million in research milestones for SLN500 and for each optioned asset, in addition to funding for Phase 1 clinical development including GMP[4] manufacturing. Silence will fund all other preclinical activities. The collaboration provides for potential added clinical and regulatory milestone payments of up to $100 million for SLN500, as well as commercial milestone payments of up to $563 million for SLN500. Should Mallinckrodt opt to license one or two additional assets, Silence could receive up to $703 million in similar clinical, regulatory, and commercial milestone payments per asset. Silence would also receive tiered, low double-digit to high-teen royalties on net sales for SLN500 and each optioned asset.
Silence Call with Investors
Dr. David Horn Solomon, Chief Executive Officer of Silence Therapeutics, will host a conference call accompanied by a live presentation for analysts and investors today at 13.00pm BST (8.00am EDT). Link to the live webcast: https://edge.media-server.com/mmc/p/d4noa4jd. Dial-in details are: Participant UK dial-in: +44 (0) 2071 928000; Participant; US Dial-in: +1 631 510 7495 Conference ID: 1576453. A presentation to accompany the call will be made available to download from https://www.silence-therapeutics.com/investors/results-reports-presentations.
On.... Investigate site.
First rns. Not showing on here.
Where are you getting these figures from $750 and $703 million?
Buy as many as you can. What a deal.
Are they worth buying at this price?
The figures are very very good..
One of the biggest deal on AIM!
Silence could receive up to $703 million in similar clinical, regulatory, and commercial milestone payments per asset.
Get in if you can...MMs will be very short soon as the market catches up here!
Just getting started. Check some of the payments to sln. Circa $750m
Company making rns - mega rns!
Good news .... let’s see it goes !!
This is going to go crazy up to Web at 1pm...
This is massive. Re rate £3 today Imo.
PLUS 2nd RNS - they’re making a further $5m investment in SLN! Double whammy!
Silence to receive a $20 million upfront payment, potential near- and long-term development and commercial milestones, and royalties on net sales
-- Silence will host a webinar today at 1:00 p.m. BST[1] to discuss the announcement
The beauty of the stock market. A company maker of a deal
10 bag time.
Collaboration..
Another blue day and holdings RNS, will this build up last and are we expecting some major news? GLA